<ehv class="tioeka"></ehv>

公海555000官网

Be the most trusted biotech company

2025-12-09

Henlius Receives NMPA Approval to Initiate Phase 2/3 Clinical Trials of HLX22 for Neoadjuvant and First-Line Treatment of HER2-Positive Breast Cancer
2025-12-08

Henlius Unveils Multi-Disciplinary Research on Serplulimab at ESMO Asia, Demonstrating Broad Clinical Value
2025-12-07

Henlius' Six Products included in China's National Reimbursement Drug List, with Innovative Breast Cancer Drug FUTUONING Added for the First Time
2025-12-05

Henlius' PD-L1 ADC HLX43 Cervical Cancer Data Debuts as Proffered Paper at 2025 ESMO Asia
2025-12-02

Henlius’ Denosumab HLX14 New Drug Application Accepted by NMPA
2025-12-01

Henlius Receives the NMPA IND Approval for Its Innovative PD-L1/VEGF Bispecific Antibody HLX37
2025-11-26

Henlius to Present Diverse Solid Tumor Pipeline at 2025 ESMO Asia: Phase 2 Cervical Cancer Data for PD-L1 ADC HLX43 Featured in Proffered Paper
2025-11-25

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Proposed Ipilimumab Biosimilar
2025-11-21

Henlius Participates in the 2025 Jefferies Global Healthcare Conference in London